Waters Corporation reported fourth-quarter 2018 non-GAAP earnings of $2.87 per share, edging past Zacks Consensus Estimate by 22 cents. The earnings are +14.3% higher compared to the same quarter a year ago.
Net sales of the Analytical laboratory instrument manufacturing company came in at $715.02 million, beating Zacks Consensus Estimate of $702.52 million. Net sales increased +4.1% year-over-year.
Major contributors to sales growth included the company’s TA product line, strong demand in Asia (especially in China), and solid performance in the pharmaceutical market.
For 2019, Waters expects its non-GAAP earnings to be in the range of $9.20-$9.45 per share. It projects net sales to grow between 4% and 6% on a constant currency basis.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.876). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.542). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties